LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Revolutionary Blood Test Enables Early Detection of Coronary Heart Disease

By LabMedica International staff writers
Posted on 01 Mar 2023
Image: PrecisionCHD is the first integrated epigenetic-genetic-based blood test for the early detection of coronary heart disease (Photo courtesy of Cardio Diagnostics)
Image: PrecisionCHD is the first integrated epigenetic-genetic-based blood test for the early detection of coronary heart disease (Photo courtesy of Cardio Diagnostics)

Cardiovascular disease (CVD) remains one of the leading causes of death globally, with coronary heart disease (CHD) being the most common type of CVD and the primary cause of heart attacks. Now, a new test aids in the early detection of coronary heart disease to better enable the management of this condition for preventing a symptomatic event such as a heart attack.

Cardio Diagnostics Holdings Inc. (Chicago, IL, USA) has launched PrecisionCHD, the first integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Using epigenetic (DNA methylation) and genetic (single nucleotide polymorphism) biomarkers along with a proprietary machine-learning model developed by analyzing billions of genomic and epigenomic data points, PrecisionCHD detects coronary heart disease with better than 75% sensitivity in both men and women.

Importantly, PrecisionCHD is accompanied by a provider-only Actionable Clinical Intelligence platform, which maps a patient’s unique biomarker profile onto modifiable risk factors like diabetes, hypertension, hypercholesterolemia, and smoking, which are considered to be critical drivers of coronary heart disease. The non-invasive, simple test offers healthcare providers a complement to traditional CHD diagnostic solutions and provides an informative, personalized patient report of CHD status.

“The launch of PrecisionCHD represents a leap forward in cardiovascular medicine. I’m beyond thrilled that we’re able to make the promise of precision cardiovascular medicine a reality,” said Robert Philibert, MD Ph.D., the company’s Chief Medical Officer and Co-Founder. “Clinicians seeking to assess coronary heart disease status in their patients no longer have to worry about their ability to obtain an exercise stress test or angiogram. Now, clinicians can have a blood sample drawn in their office or a kit sent to their patient’s home for this highly sensitive test.”

Related Links:
Cardio Diagnostics Holdings Inc. 

Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Automatic CLIA Analyzer
Shine i9000
Sample Transportation System
Tempus1800 Necto

Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Pathology

view channel
Image: Determining EG spiked into medicinal syrups: Zoomed-in images of the pads on the strips are shown. The red boxes show where the blue color on the pad could be seen when visually observed (Arman, B.Y., Legge, I., Walsby-Tickle, J. et al. https://doi.org/10.1038/s41598-025-26670-1)

Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups

Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
GLOBE SCIENTIFIC, LLC